Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
A novel approach to screening
Freenome’s intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages.
Powered by a rigorous clinical program
Our research programs drive discovery, development, and validation of our early cancer detection tests.
Multi-disciplinary leadership with purpose
We bring together passionate creators and ambitious builders. Together, we are relentless in pushing for what’s possible in early cancer detection.
Join our team
Are you ready to make a significant impact? Explore our job openings and see how your skills can help us redefine the future of cancer screening.
Outpacing cancer starts with early detection
Cancer screening should be easy and accessible for everyone. Freenome is an early cancer detection company developing tests to find cancer in its earliest, most treatable stages, with the ease of a standard blood draw.
Outpacing cancer starts with early detection
Cancer screening should be easy and accessible for everyone. Freenome is an early cancer detection company developing tests to find cancer in its earliest, most treatable stages, with the ease of a standard blood draw.
A new approach to cancer screening
Freenome is pioneering Personalized Cancer Detection (PCD), which matches blood-based tests to the cancers most relevant for each person based on their health profile. Built on a multiomics platform that analyzes multiple biological signals in the blood, PCD also delivers screening optimized for each type of cancer.
SimpleScreen: making cancer screening easy and accessible
Freenome’s portfolio of SimpleScreen blood-based screening tests is how we deliver Personalized Cancer Detection – screening as unique as each individual patient.
Learn more about our SimpleScreen CRC and SimpleScreen Lung tests, the first offerings in what will be an expanding portfolio designed to address a broad range of patient risks and screening needs.
Building the future of early detection
Since our founding in 2014, Freenome has been building the future of early cancer detection by combining cutting-edge science, advanced AI and machine learning technology, and bold thinking. Discover the vision, values and team behind Freenome’s mission to change how cancer is detected.